Suppr超能文献

日本新冠疫情大流行期间肺癌手术安全性及影响的真实世界证据。

Real-world evidence of safety and influence for lung cancer surgery under COVID-19 pandemic in Japan.

作者信息

Kato Taketo, Katsuya Ryotaro, Okado Shoji, Sato Keiyu, Noritake Osamu, Nakanishi Keita, Noguchi Misa, Kadomatsu Yuka, Ueno Harushi, Ozeki Naoki, Nakamura Shota, Fukumoto Koichi, Chen-Yoshikawa Toyofumi Fengshi

机构信息

Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

J Thorac Dis. 2023 Feb 28;15(2):542-551. doi: 10.21037/jtd-22-1289. Epub 2023 Feb 3.

Abstract

BACKGROUND

The COVID-19 pandemic has affected the clinical practice of lung cancer surgery in Japan, but few studies have revealed the real situation of surgical practice for lung cancer in this country. This latest information will help us to decide the future direction of lung cancer surgery under pandemic circumstances.

METHODS

We collected data from patients with primary lung cancer who underwent thoracic surgery between 2018 and 2021. To investigate the impact of the COVID-19 pandemic on lung cancer surgery, we compared between 2018-2019 (prepandemic group) and 2020-2021 (pandemic group) in the respect of patient characteristics, pathological findings, and short-term outcome after lung cancer resection by Mann-Whitney and Fisher's exact tests. Moreover, the monthly number of surgeries for lung cancer in our institution during 2020-2021 was compared with the number of newly diagnosed COVID-19 patients in Japan by Spearman correlation analysis.

RESULTS

From 2018 through 2021, 936 patients with primary lung cancer underwent surgical intervention in our institute and were included in this study. The number of surgeries did not decrease in the pandemic group (n=443) compared with that in the prepandemic group (n=493). Tumor and invasive size in stage I which was measured by pathologist were significantly larger in the pandemic group than in the prepandemic group (tumor size: P=0.031, invasive size: P<0.001). In terms of postoperative short-term outcome, the median hospital stay was 6 days, 30-day mortality was 2, and morbidity was around 20% in both groups. Only one patient suffered from COVID-19 infection 5 months after right upper lobectomy. An increased ratio of newly diagnosed COVID-19 cases in Japan was negatively correlated with the number of surgeries for lung cancer in our institution in the next month (r=-0.393, P=0.007), although there was no correlation in the present or the month after next.

CONCLUSIONS

Even during the COVID-19 pandemic period, lung cancer surgery could be performed safely and in a sustainable manner. However, pathological findings of lung cancer tended to be progressive in early-stage lung cancer.

摘要

背景

新冠疫情影响了日本肺癌手术的临床实践,但很少有研究揭示该国肺癌手术的实际情况。这些最新信息将有助于我们确定疫情背景下肺癌手术的未来方向。

方法

我们收集了2018年至2021年间接受胸外科手术的原发性肺癌患者的数据。为了调查新冠疫情对肺癌手术的影响,我们通过曼-惠特尼检验和费舍尔精确检验,比较了2018 - 2019年(疫情前组)和2020 - 2021年(疫情组)在患者特征、病理结果以及肺癌切除术后短期结局方面的差异。此外,通过斯皮尔曼相关性分析,比较了2020 - 2021年我们机构每月肺癌手术例数与日本新增新冠确诊患者数。

结果

2018年至2021年期间,936例原发性肺癌患者在我们研究所接受了手术干预并纳入本研究。与疫情前组(n = 493)相比,疫情组(n = 443)的手术例数并未减少。病理科医生测量的I期肿瘤大小和浸润范围在疫情组显著大于疫情前组(肿瘤大小:P = 0.031,浸润范围:P < 0.001)。在术后短期结局方面,两组的中位住院时间均为6天,30天死亡率均为2例,发病率均约为20%。仅1例患者在右上叶切除术后5个月感染了新冠病毒。日本新增新冠确诊病例数的增加比例与我们机构下个月的肺癌手术例数呈负相关(r = -0.39, P = 0,007),尽管在当月或下下个月无相关性。

结论

即使在新冠疫情期间,肺癌手术仍可安全且持续地进行。然而,早期肺癌的病理结果有进展的趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f96f/9992575/6597bafa04f9/jtd-15-02-542-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验